ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Johnson & Johnson Innovation, an arm of J&J focused on early-stage research, has unveiled 12 new pacts with biotech firms and research institutions. The pacts span diseases including cancer, arthritis, dementia, and diabetes. Among the new partners is Energesis Pharmaceuticals, which is trying to treat metabolic diseases by stimulating the formation of brown fat. J&J also has taken stakes in Navitor Pharmaceuticals, which is developing modulators of the mTORC1 pathway to treat diabetes, and Rodin Therapeutics, a biotech firm developing epigenetic modulators for cognitive disorders.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter